In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Apergy Corporation (NYSE:APY), vTv...
--- Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway -
Company announcement - No. 03 / 2019
Stock Monitor: Cytokinetics Post Earnings Reporting